NCT06855498 (STOP-LTR) is a Phase 3 clinical trial of povorcitinib in Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.

Who is sponsoring NCT06855498?

NCT06855498 is sponsored by Incyte Corporation.

What drugs are being tested in NCT06855498?

Interventions in NCT06855498: povorcitinib.

What condition does NCT06855498 study?

NCT06855498 studies Hidradenitis Suppurativa (HS).

Is NCT06855498 still recruiting?

NCT06855498 is currently recruiting now. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT06855498: STOP-LTR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Recruiting now Phase 3 Last updated 8 April 2026

What this trial tests

Phase 3 trial testing povorcitinib in Hidradenitis Suppurativa (HS) in 600 participants. Currently enrolling.

Timeline

28 February 2025

Primary endpoint
28 February 2028

28 February 2028

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	600
Start date	28 February 2025
Primary completion	28 February 2028
Estimated completion	28 February 2028
Sites	316 locations across Italy, Poland, South Korea, Denmark, Netherlands, Belgium, Bulgaria, United States

Drugs / interventions tested

povorcitinib — full drug profile →

Conditions studied

Hidradenitis Suppurativa (HS) — all drugs for Hidradenitis Suppurativa (HS) →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Hidradenitis Suppurativa (HS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of povorcitinib

Trials testing the same drug.

NCT05851443 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate · Phase 2 · recruiting

Other recruiting trials for Hidradenitis Suppurativa (HS)

Currently open trials in the same condition.

NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
NCT07287644 — A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa · Phase 2, PHASE3 · recruiting
NCT07155239 — 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) · Phase 1 · recruiting
NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
NCT07109765 — Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06855498 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06855498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing